Filing summary
Filing and period: The supplied filing is MEI Pharma, Inc.’s Form 10-K for the fiscal year ended June 30, 2012, filed September 17, 2012. This does not match the request metadata identifying Lite Strategy, Inc. and 2010 Q4; verify the issuer and reporting period before relying on this summary.
Business context
MEI Pharma was a development-stage oncology company with no operating revenue, developing ME-143 and ME-344 and, after an August 2012 asset acquisition, Pracinostat. Its common stock began trading as MEIP on July 2, 2012. Novogen remained its majority shareholder as of the filing date.
Financial performance and position
| Metric | FY ended June 30, 2012 | FY ended June 30, 2011 |
|---|---|---|
| Revenue | None from operations | None from operations |
| Research and development expense | $4.915 million | $2.115 million |
| General and administrative expense | $3.479 million | $4.336 million |
| Operating loss | $8.394 million | $6.451 million |
| Net loss | $7.523 million | $6.781 million |
| Basic and diluted loss per share | $0.56 | $0.89 |
| Net cash used in operations | $7.081 million | $6.501 million |
| Cash and cash equivalents at year-end | $6.202 million | $3.858 million |
For the quarter ended June 30, 2012, net loss was $2.101 million, versus $1.642 million in the comparable quarter. The filing reports no operating revenue, so revenue-based margins are not meaningful. At June 30, 2012, total assets were $6.373 million, current liabilities $1.774 million, and stockholders’ equity $4.599 million. The balance sheet lists no borrowings; it reports accounts payable, accrued liabilities, and no remaining derivative liabilities. Working capital was approximately $4.574 million.
Changes and financing
- R&D expense rose $2.800 million, primarily due to ME-143 and ME-344 development, patent costs, and increased staffing. G&A fell $857,000, largely reflecting lower transaction-related professional fees and the end of Novogen service charges.
- Net loss increased $742,000 year over year; loss per share improved as the weighted-average share count increased substantially.
- Financing provided $9.425 million net cash in FY2012, including $9.831 million net proceeds from common-stock issuance, offset by $406,000 of financing costs. The May 2012 rights offering raised $4.8 million net.
- Common shares outstanding increased from 8.9 million at June 30, 2011 to 20.5 million at June 30, 2012. Novogen’s preferred stock was convertible initially into 4.827 million additional common shares, subject to possible milestone-related increase.
Outlook, risks, and notable items
- Management estimated that $6.2 million of cash would fund operations only until early calendar 2013 and said additional capital was needed. The auditor included a going-concern explanatory paragraph, citing recurring losses, no current revenue source, and limited financing; substantial doubt about continued operations was noted.
- ME-143 Phase I enrolled 15 patients; the company reported general tolerability with one serious infusion reaction at the highest dose and a maximum tolerated dose of 20 mg/kg. Management expected to begin a Phase II combination trial in triple-negative breast cancer in Q1 calendar 2013.
- ME-344 Phase I was underway; final safety and pharmacokinetic data were expected in Q2 calendar 2013. These were management expectations, not guaranteed outcomes.
- The August 2012 Pracinostat acquisition, completed after fiscal year-end, involved 1,174,536 shares valued at $500,000, with potential clinical, regulatory, and sales milestone payments up to $75.2 million plus sales-based earn-outs. Management planned a Phase II trial in a hematologic disorder around mid-2013.
- Key risks include further financing needs and dilution, clinical and regulatory failure, competition, dependence on third-party trial and manufacturing providers, intellectual-property challenges, and potential Nasdaq bid-price noncompliance. The filing said the company did not expect to regain the $1.00 minimum bid-price requirement within the initial grace period ending September 24, 2012.
- Novogen announced a proposed distribution of its MEI shares to its shareholders, subject to approvals; completion was uncertain. The filing also describes Novogen’s control of voting outcomes and potential conflicts of interest.
Investor verification priorities
- Confirm that this MEI Pharma FY2012 filing—not a Lite Strategy 2010 Q4 filing—is the intended source.
- Check subsequent filings for actual cash runway, financing, going-concern developments, and any changes to operations.
- Verify clinical-trial enrollment, safety findings, trial start dates, and whether stated data and development timelines were achieved.
- Review the dilution and capitalization implications of outstanding warrants, convertible preferred stock, and the Pracinostat milestone and earn-out terms.
- Check the outcomes of Nasdaq listing compliance and Novogen’s proposed share distribution.